136 related articles for article (PubMed ID: 27344681)
1. [Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide].
Kitanaka A; Shimoda K
Gan To Kagaku Ryoho; 2016 May; 43(5):535-8. PubMed ID: 27344681
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of anagrelide in childhood essential thrombocythemia.
Kanai A; Morokawa H; Matsuda K; Shimazaki E; Nakazawa Y
Pediatr Int; 2017 Sep; 59(9):1017-1018. PubMed ID: 28707720
[No Abstract] [Full Text] [Related]
3. Long-term use of anagrelide in the treatment of children with essential thrombocythemia.
Lackner H; Urban C; Benesch M; Moser A; Sovinz P; Schwinger W; Dornbusch HJ
Eur J Haematol; 2006 Oct; 77(4):358-9. PubMed ID: 16856926
[No Abstract] [Full Text] [Related]
4. Treatment of essential thrombocythemia in childhood.
Scherer S; Ferrari R; Rister M
Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
[TBL] [Abstract][Full Text] [Related]
5. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
6. Treatment of essential thrombocythemia with anagrelide.
Chintagumpala MM; Kennedy LL; Steuber CP
J Pediatr; 1995 Sep; 127(3):495-8. PubMed ID: 7658287
[TBL] [Abstract][Full Text] [Related]
7. [Essential thrombocythemia: therapy with anagrelide].
Mazzucconi MG; Ferrari A; Balduini CL
Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
[No Abstract] [Full Text] [Related]
8. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy.
Wong RS; Lam LW; Cheng G
Ann Hematol; 2008 Aug; 87(8):683-4. PubMed ID: 18299832
[No Abstract] [Full Text] [Related]
9. Treatment of essential thrombocythemia with anagrelide.
Silverstein MN; Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
[TBL] [Abstract][Full Text] [Related]
10. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.
Cacciola RR; Francesco ED; Giustolisi R; Cacciola E
Br J Haematol; 2004 Sep; 126(6):885-6. PubMed ID: 15352995
[No Abstract] [Full Text] [Related]
11. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
Andersson BS
Hematology; 2002 Jun; 7(3):173-7. PubMed ID: 12243981
[No Abstract] [Full Text] [Related]
12. Anagrelide and the CALR mutation allele burden in essential thrombocythemia.
Atkinson E; Bakri M; Hayat A; Langabeer SE
Exp Oncol; 2018 Jun; 40(2):152-153. PubMed ID: 29949532
[No Abstract] [Full Text] [Related]
13. [Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide].
Kajiguchi T; Kamoshita S; Ito T; Yagi M; Kimura T
Rinsho Ketsueki; 2017; 58(2):119-125. PubMed ID: 28321088
[TBL] [Abstract][Full Text] [Related]
14. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
Cacciola RR; Cipolla A; Di Francesco E; Giustolisi R; Cacciola E
Am J Hematol; 2005 Sep; 80(1):81-3. PubMed ID: 16138352
[TBL] [Abstract][Full Text] [Related]
15. Is anagrelide safe during pregnancy?
Cornet N; Vialard F; Mir O; Berveiller P
J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):697-699. PubMed ID: 28866127
[No Abstract] [Full Text] [Related]
16. Essential thrombocythemia in a child: management with anagrelide.
Chintagumpala MM; Steuber CP; Mahoney DH; Ogden AK; Fernbach DJ
Am J Pediatr Hematol Oncol; 1991; 13(1):52-6. PubMed ID: 2029080
[TBL] [Abstract][Full Text] [Related]
17. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
18. [Anagrelide for treatment of patients with essential thrombocythaemia].
Boban A; Sertić D; Radman I; Zupancić-Salek S; Zadro R; Labar B
Lijec Vjesn; 2008; 130(5-6):141-5. PubMed ID: 18792562
[TBL] [Abstract][Full Text] [Related]
19. Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine.
Dziewierz A; Olszanecka A; Wiliński J; Rakowski T; Kleczyński P; Dubiel JS; Dudek D
Int J Cardiol; 2012 Oct; 160(2):e31-2. PubMed ID: 22406466
[No Abstract] [Full Text] [Related]
20. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
